• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-Altering Pain 

May 11, 2022
10,000+ Implants

– Adoption of SPRINT® PNS System Doubled Within the Last Year – 

Cleveland, Ohio – May 12, 2022- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System. The SPRINT System provides a low-risk alternative to opioids and does not require ablation, surgery, or permanent device implantation.  

SPR Therapeutics commercially launched the SPRINT PNS System in 2017 with the 5,000th treatment occurring in June of 2021. In the last year, the company experienced growing demand for the SPRINT System, doubling the total number of patients treated. As a result, the company is expanding its commercial footprint across the U.S. while continuing to innovate its product and increase its already significant clinical research in support of peripheral nerve stimulation (PNS) to assure that the needs of millions of Americans living with pain can be met.  

David Reece, DO, Director of Neuromodulation and Orthobiologics at APMI Orthopaedics, Sports Health & Regenerative Medicine, performed the 10,000th treatment on a patient suffering from chronic shoulder pain. The patient received Bimodal PNS™, unique to the SPRINT PNS System, which deploys two pain relief mechanisms believed to complement each other in which nerves are stimulated with and without muscle activation.  

Dr. Reece noted, “There are very few treatments we have for the many patients who seek care for shoulder pain, and the SPRINT System fills an important gap in the care continuum for these patients. The opportunity to delay and often prevent surgical intervention, permanent implants, and/or neurolytic procedures is a tremendous benefit while evading the addictive challenges presented by opioids.” In discussing the 10,000th treatment, he added, “Optimal perineural placement of the SPR leads, with this novel bimodal approach, can be achieved via ultrasound and/or fluoroscopic guidance; making the SPRINT procedure accessible to nearly all interventional pain management physicians who routinely utilize image-guidance in their pain practice. For many of my colleagues, I see SPRINT PNS as an important addition to their treatment algorithm and a potential gateway to their use of neuromodulation.” 

“From our commercial launch to today, SPRINT has offered patients the potential to return to the lives they want to live and that is the milestone we recognize and celebrate today,” said SPR Therapeutics CEO Maria Bennett. “As a company we are committed to helping patients living with pain, and we are proud of the significant and rapid advances we are seeing as we work to establish SPRINT as the treatment of choice for these patients.” 

About the SPRINT® PNS System  

The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line™ PNS option uniquely designed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days. Recognized by leading pain management centers, the breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options. 

The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. 

For additional information regarding safety and efficacy, visit www.SprintPNS.com. 

About SPR Therapeutics, Inc. 
SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally-invasive, drug-free, surgery-free solution to manage their acute and chronic pain.  

More information can be found at www.SPRTherapeutics.com. 

SPR Contacts: 
Mark Stultz 
Senior Vice President 
mstultz@sprtherapeutics.com
612.770.0390  

Dave Folkens 
Public Relations 
dfolkens@sprtherapeutics.com 
612.978.6547 

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: News
Previous Post:Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
Next Post:Real-World Evidence of Significant and Sustained Outcomes Following 60-Day Peripheral Nerve Stimulation Treatment for Chronic Pain

Reader Interactions

Comments

  1. Carolyn hunt

    May 31, 2022 at 8:07 pm

    Do I disconnect the cord from the box after 6 hours and when do i reconnect the cord

    Reply
    • SPR Therapeutics

      June 1, 2022 at 5:12 pm

      Hello Carolyn – Thank you so much for your comment! We’d be glad to help answer your questions about using the SPRINT PNS System. Please reach out to our Patient Support team by calling 1-844-378-9108 and selecting option 1 from the menu. If more convenient, you may email them at patientsupport@sprtherapeutics.com.

      Reply
  2. Robert Cahill

    August 30, 2022 at 4:14 pm

    Had my Sprint in for two weeks for rotator cuff pain. Wonderful results! I am in need of an MRI for diagnostic purposes for a possible stress fracture in my pelvis. Could you please tell me about the procedure to remove the lead prior to an MRI? Thanks

    Reply
    • SPR Therapeutics

      August 31, 2022 at 1:49 pm

      Hi Robert, we are so glad to hear that you are getting wonderful results! We will have your SPR Representative contact you to discuss the procedure.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo